Physician profile
Steven E Holroyd
NPI 1871557942
$2,552.68
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $514 · 2021: $467 · 2022: $469 · 2023: $442 · 2024: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $519.71 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $351.24 | 2020-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $338.03 | 2019-2024 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $297.95 | 2019-2024 | Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $246.21 | 2019-2024 | Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $216.80 | 2019-2020 | |
| Indivior INC. | $138.38 | 2022-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $136.06 | 2019-2023 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $76.36 | 2022-2023 | Hetlioz, Fanapt |
| Alkermes, INC. | $74.31 | 2020-2023 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $62.79 | 2021-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $54.36 | 2019 | |
| Eisai INC. | $27.93 | 2021 | |
| Neuronetics, INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Holroyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.